PROJECT SUMMARY/ABSTRACT
Over half of all children severely hurt their teeth through physical injury or carious legion, resulting in the
performance of 4.7M endodontic procedures per year in the pediatric and young adult population. Maintenance
of vital pulp in the tooth is critical for the ability to fight future infections, prevent fracture, and retain the tooth,
particularly for immature permanent teeth without fully developed roots. Existing treatment options include non-
vital therapies, such as apexification and root canal therapy, vital pulp therapies, which preserve some existing
pulp but do not maintain vital pulp throughout the dental canal, and revascularization therapy, which suffers
from high rates of adverse events. Treatment with Vital-Dent, a hydrogel material that supports the
regeneration of vital pulp tissue for the restoration of pulp throughout the dental canal, will increase tooth
retention and promote resistance to fracture and infection. Vital-Dent is an acellular, drug-free hydrogel that
provides obturation and pulp regeneration for regenerative endodontic procedures. Vital-Dent consists of two
biopolymers (porcine derived gelatin with added unfractionated heparin) and photoinitiator dissolved in saline.
The liquid hydrogel precursor is placed into the pulp canal and then is photocrosslinked. The hydrogel works
as a barrier to influx of blood into the treated tooth root, inhibiting the acute inflammatory response to thrombus
formation, with the gelatin supporting cellular migration into the hydrogel from the periapical space. The
heparin supplement promotes swelling of the gelatin hydrogel to ensure the full obturation and the barrier
function. The extensive testing completed to date demonstrates the regeneration of pulp tissue and
maintenance of tooth vitality with Vital-Dent. Phase I results showed that Vital-Dent doubled the incidence of
apex closure relative to revascularization. This is the paramount outcome for pediatric indications, as continued
tooth development greatly increases tooth survival. The work proposed here represents a significant step
towards bringing Vital-Dent to the clinic. The Vital-Dent manufacturing process will be scaled up and the
product formulation will be optimized to include cGMP precursor biomacromolecules while maintaining the
equivalent physical properties and biocompatibility of the final hydrogel. This aim will result in the manufacture
of a fully cGMP-compliant batch of Vital-Dent. The mechanical and functional properties of the final Vital-Dent
formulation will be characterized, and an in vivo study will evaluate the effectiveness of Vital-Dent. Finally, we
will perform biocompatibility testing to assess for cytotoxicity, sensitization potential, irritation, and acute and
subacute toxicity. The proposed studies have been designed to support the filing for FDA clearance of Vital-
Dent, a critical step towards adoption of Vital-Dent.